老年人使用多种药物时与奈玛特韦-利托那韦的药物相互作用。
Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications.
机构信息
Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
Centre for Outcomes Research and Evaluation, McGill University Health Centre, Montreal, Quebec, Canada.
出版信息
JAMA Netw Open. 2022 Jul 1;5(7):e2220184. doi: 10.1001/jamanetworkopen.2022.20184.
Abstract
This quality improvement study uses data from the MedSafer trial to evaluate drug-drug interactions between nirmatrelvir-ritonavir and maintenance medications to identify use of potentially inappropriate medications in older adults with polypharmacy.
摘要
本质量改进研究使用了 MedSafer 试验的数据，评估了奈玛特韦-利托那韦与维持性药物之间的药物相互作用，以确定在服用多种药物的老年患者中潜在不适当药物的使用情况。
相似文献
1
Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications.老年人使用多种药物时与奈玛特韦-利托那韦的药物相互作用。
JAMA Netw Open. 2022 Jul 1;5(7):e2220184. doi: 10.1001/jamanetworkopen.2022.20184.
2
Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy.使用尼马曲韦/利托那韦治疗癫痫患者：国际抗癫痫联盟以色列分会的最新进展。
Epilepsia. 2022 May;63(5):1276-1278. doi: 10.1111/epi.17212. Epub 2022 Mar 9.
3
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.奈玛特韦利托那韦片的处方：如何识别和管理药物相互作用。
Ann Intern Med. 2022 May;175(5):744-746. doi: 10.7326/M22-0281. Epub 2022 Mar 1.
4
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series.奈玛特韦-利托那韦与口服抗凝剂潜在药物相互作用的管理：病例系列
J Thromb Thrombolysis. 2022 Nov;54(4):583-586. doi: 10.1007/s11239-022-02707-4. Epub 2022 Oct 18.
5
Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration.应对新冠患者中奈玛特韦/利托那韦的潜在药物相互作用：来自以色列跨部门合作的视角
Clin Pharmacol Ther. 2022 Dec;112(6):1156-1158. doi: 10.1002/cpt.2610. Epub 2022 May 5.
6
Prevalence and Management of Medication Interactions with Nirmatrelvir-Ritonavir at a Large Urban Academic Medical Center: An Observational Study.大型城市学术医疗中心中与奈玛特韦-利托那韦药物相互作用的发生率及管理：一项观察性研究
J Gen Intern Med. 2024 Aug;39(10):1948-1950. doi: 10.1007/s11606-024-08750-6. Epub 2024 Apr 10.
7
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?口服奈玛特韦/利托那韦治疗新冠病毒病：黑暗中的曙光？
Antibiotics (Basel). 2022 Feb 9;11(2):220. doi: 10.3390/antibiotics11020220.
8
Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal.需要住院治疗的实体器官移植受者使用奈玛特韦/利托那韦时他克莫司浓度高于治疗水平：一项使用利福平进行逆转的病例系列研究。
Open Forum Infect Dis. 2022 May 13;9(7):ofac238. doi: 10.1093/ofid/ofac238. eCollection 2022 Jul.
9
Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.与考比司他或利托那韦增强的埃替格韦的药物相互作用。
AIDS Rev. 2016 Apr-Jun;18(2):101-11.
10
Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions.药代动力学增强剂（考比司他/利托那韦）和药物相互作用的潜力。
Ir J Med Sci. 2020 May;189(2):693-699. doi: 10.1007/s11845-019-02125-1. Epub 2019 Nov 18.
引用本文的文献
1
SARS-CoV-2 rebound and post-acute mortality and hospitalization among patients admitted with COVID-19: cohort study.新型冠状病毒肺炎患者中严重急性呼吸综合征冠状病毒2型的反弹及急性后期死亡率和住院率：队列研究
Nat Commun. 2025 Jul 28;16(1):6924. doi: 10.1038/s41467-025-61737-7.
2
Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter: An Overview of Clinical Data.帕罗韦德与CYP3A酶和P-糖蛋白转运体的药代动力学相互作用：临床数据概述
Curr Drug Metab. 2024;25(9):639-652. doi: 10.2174/0113892002320326250123082112.
3
Polypharmacy or potentially inappropriate medications among older adults with COVID-19 in a secondary hospital in China and their association with mortality.中国一家二级医院中新冠肺炎老年患者的多重用药或潜在不适当用药情况及其与死亡率的关联。
Sci Rep. 2025 Jan 2;15(1):166. doi: 10.1038/s41598-024-84064-1.
4
Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an insight.减轻帕罗韦德™引起的药物相互作用毒性：见解
Front Pharmacol. 2024 Nov 26;15:1496630. doi: 10.3389/fphar.2024.1496630. eCollection 2024.
5
Prevalence of medication overload among older people with HIV: a MedSafer study.老年人 HIV 患者药物过量的流行情况：MedSafer 研究。
BMC Infect Dis. 2024 Oct 25;24(1):1204. doi: 10.1186/s12879-024-10105-9.
6
Paxlovid (Nirmatrelvir/Ritonavir)-Induced Tacrolimus Toxicity in Organ Transplant Recipients - A Review on Drug Interactions Involving CYP3A Enzymes.帕罗韦德（奈玛特韦/利托那韦）诱导器官移植受者发生他克莫司毒性——关于涉及CYP3A酶的药物相互作用的综述
Curr Drug Saf. 2025;20(3):291-302. doi: 10.2174/0115748863331165240821194206.
7
Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study.用于合理使用奈玛特韦/利托那韦的药物相互作用管理系统评估：一项回顾性观察研究。
J Pharm Health Care Sci. 2024 Sep 3;10(1):54. doi: 10.1186/s40780-024-00376-4.
8
A Structural Comparison of Oral SARS-CoV-2 Drug Candidate Ibuzatrelvir Complexed with the Main Protease (M) of SARS-CoV-2 and MERS-CoV.口服抗SARS-CoV-2候选药物依布扎特雷韦与SARS-CoV-2和MERS-CoV主要蛋白酶（M）复合的结构比较
JACS Au. 2024 Jul 30;4(8):3217-3227. doi: 10.1021/jacsau.4c00508. eCollection 2024 Aug 26.
9
Telemedicine for Prescribing Nirmatrelvir/Ritonavir: Safety, Logistics, and Challenges.用于开具奈玛特韦/利托那韦处方的远程医疗：安全性、物流与挑战
Open Forum Infect Dis. 2024 May 14;11(7):ofae283. doi: 10.1093/ofid/ofae283. eCollection 2024 Jul.
10
Prevalence and Management of Medication Interactions with Nirmatrelvir-Ritonavir at a Large Urban Academic Medical Center: An Observational Study.大型城市学术医疗中心中与奈玛特韦-利托那韦药物相互作用的发生率及管理：一项观察性研究
J Gen Intern Med. 2024 Aug;39(10):1948-1950. doi: 10.1007/s11606-024-08750-6. Epub 2024 Apr 10.
本文引用的文献
1
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
2
Nirmatrelvir-ritonavir for COVID-19.用于治疗新冠肺炎的奈玛特韦片/利托那韦片组合包装
CMAJ. 2022 Feb 14;194(6):E218. doi: 10.1503/cmaj.220081. Epub 2022 Feb 3.
3
The MedSafer Study-Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial.《MedSafer 研究-电子决策支持在老年住院患者中减药的应用：一项集群随机临床试验》。
JAMA Intern Med. 2022 Mar 1;182(3):265-273. doi: 10.1001/jamainternmed.2021.7429.
4
SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.SQUIRE 2.0（卓越质量改进报告标准）：通过详细的共识过程制定的修订版出版指南。
BMJ Qual Saf. 2016 Dec;25(12):986-992. doi: 10.1136/bmjqs-2015-004411. Epub 2015 Sep 14.
Zotero 插件